Mitochondrially Localized ERK2 Regulates Mitophagy and Autophagic Cell Stress: Implications for Parkinson's Disease
Overview
Affiliations
Degenerating neurons of Parkinson's disease (PD) patient brains exhibit granules of phosphorylated extracellular signal-regulated protein kinase 1/2 (ERK1/2) that localize to autophagocytosed mitochondria. Here we show that 6-hydroxydopamine (6-OHDA) elicits activity-related localization of ERK1/2 in mitochondria of SH-SY5Y cells, and these events coincide with induction of autophagy and precede mitochondrial degradation. Transient transfection of wildtype (WT) ERK2 or constitutively active MAPK/ERK Kinase 2 (MEK2-CA) was sufficient to induce mitophagy to a degree comparable with that elicited by 6-OHDA, while constitutively active ERK2 (ERK2-CA) had a greater effect. We developed green fluorescent protein (GFP) fusion constructs of WT, CA, and kinase-deficient (KD) ERK2 to study the role of ERK2 localization in regulating mitophagy and cell death. Under basal conditions, cells transfected with GFP-ERK2-WT or GFP-ERK2-CA, but not GFP-ERK2-KD, displayed discrete cytoplasmic ERK2 granules of which a significant fraction colocalized with mitochondria and markers of autophagolysosomal maturation. The colocalizing GFP-ERK2/mitochondria granules are further increased by 6-OHDA and undergo autophagic degradation, as bafilomycin-A, an inhibitor of autolysosomal degradation, robustly increased their detection. Interestingly, increasing ERK2-WT or ERK2-CA expression was sufficient to promote comparable levels of macroautophagy as assessed by analysis of the autophagy marker microtubule-associated protein 1 light chain 3 (LC3). In contrast, the level of mitophagy was more tightly correlated with ERK activity levels, potentially explained by the greater localization of ERK2-CA to mitochondria compared to ERK2-WT. These data indicate that mitochondrial localization of ERK2 activity is sufficient to recapitulate the effects of 6-OHDA on mitophagy and autophagic cell death.
Mantey I, Langerscheidt F, Cakmak Durmaz C, Baba N, Burghardt K, Karakaya M Genes (Basel). 2025; 16(2).
PMID: 40004527 PMC: 11855138. DOI: 10.3390/genes16020198.
Meng K, Jia H, Hou X, Zhu Z, Lu Y, Feng Y Biomedicines. 2025; 13(2).
PMID: 40002740 PMC: 11852430. DOI: 10.3390/biomedicines13020327.
Sisalli M, DApolito E, Cuomo O, Lombardi G, Tufano M, Annunziato L Cell Death Dis. 2025; 16(1):52.
PMID: 39875361 PMC: 11775118. DOI: 10.1038/s41419-025-07339-z.
Riaz Z, Richardson G, Jin H, Zenitsky G, Anantharam V, Kanthasamy A Mol Neurodegener. 2024; 19(1):87.
PMID: 39578912 PMC: 11585115. DOI: 10.1186/s13024-024-00774-0.
Stevanovic D, Vucicevic L, Misirkic-Marjanovic M, Martinovic T, Mandic M, Harhaji-Trajkovic L Int J Mol Sci. 2024; 25(19).
PMID: 39408988 PMC: 11476739. DOI: 10.3390/ijms251910659.